We are excited to announce that Cmed has today joined the AIXIAL Group and ALTEN Group.

ALTEN is a world leader in Engineering and Technology consulting with 37,000 engineers and scientists located in more than 30 countries throughout the world. It serves customers in a range of industries and has a depth and breadth of experience and expertise across life sciences, software development and artificial intelligence.

AIXIAL Group, an ALTEN company, is a CRO renowned for its flexible and functional resourcing. Through this acquisition, the AIXIAL Group continues to build its global presence with over 1,000 employees. Cmed’s experience, expertise and technology approach perfectly align with the AIXIAL Group’s vision to provide expert services to clients and transform the clinical trials landscape for the benefit of patients.

Cmed Technology is now able to offer an even greater breadth and capability to improve client trial operations through the substantial expertise, capabilities and scale of ALTEN and AIXIAL.

A copy of the recent press releases from ALTEN, Cmed and Aixial are available at this link for your information.

Latest articles

Digital transformation can happen for any sponsor: How small and mid-sized biopharmaceutical companies can easily achieve digital innovation for their clinical data

In just a couple of decades, information technology has undergone a radical transformation –a sweeping evolution from floppy drives to data warehouses to data lakes. Our industry has unfortunately not ridden the arc of technology at the pace of other…

Read article

A better way to drive your digital transformation

As the ways in which clinical trials are conducted and monitored continue to modernize at pace, there is an urgent need for digital transformation in the industry. If sponsors are to realize their goals of running flexible, decentralized trials (DCT),…

Read article

Five predictions for the future of decentralized clinical trials

The message was clear from industry leaders last year – today’s clinical trials need decentralized solutions. More complexity means intensive data capture and continuous flows are essential, and vital strategic decisions rely on real-time data analysis and intelligence. Existing point…

Read article